R. Digumarti

发表

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel in Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer

S. Nag, J. Madhavan, P. Julka, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Johan Vansteenkiste, G. Scagliotti, Keunchil Park, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.

S. Nag, J. Madhavan, P. Parikh, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.

B. Coiffier, H. Gómez, P. Zinzani, 2012, The Lancet. Oncology.

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.

A. Buzdar, B. Xu, Bing-he Xu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study

Ravi Kumar, S. Bondarde, S. Patil, 2016, Breast Cancer Research and Treatment.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

R. Betts, J. D. De Waele, B. Suh, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.

G. Bhattacharyya, D. Gerber, P. Bapsy, 2014, Lung cancer.